Apimeds shares rise 11.74% premarket after merging with Mindwave and securing $100M in private financing.

Apimeds Pharmaceuticals (APUS) surged 11.74% in premarket trading following the announcement of its strategic merger with Mindwave Innovations and the completion of a $100 million private investment in equity (PIPE). The merger integrates biotech growth with AI-driven digital treasury strategies, including the activation of 1,000 bitcoins to fund yield generation. This move signals a pivot toward AI and blockchain-driven financial innovation, likely boosting investor confidence. Earlier news of a board member resignation and routine corporate updates (e.g., CEO agreement revisions) were overshadowed by the merger’s scale and forward-looking vision, which aligns with the stock’s sharp premarket rise.